# Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

> **NCT04074837** · PHASE1 · COMPLETED · sponsor: **Neuronascent, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** NNI-362
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04074837
- **Lead sponsor:** Neuronascent, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-01
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-08-15
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04074837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04074837, "Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04074837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*